Desmopressin sublingual - Ferring Pharmaceuticals

Drug Profile

Desmopressin sublingual - Ferring Pharmaceuticals

Alternative Names: DDAVP Melt; FE 992026; Minirin Melt; NOCDURNA; Nocdurna; Nokdurna; Noqdirna; Noqturina; Oral lyophilisate desmopressin

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Antidiuretics; Antihaemorrhagics; Hormones; Urologics; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetes insipidus; Enuresis; Nocturia
  • Phase II Overactive bladder

Most Recent Events

  • 25 Jun 2018 Registered for Nocturia in USA (Sublingual)
  • 13 Nov 2017 Ferring Pharmaceuticals initiates enrolment in the phase III AWAKEN trial for Nocturia in Hungary (EudraCT2017-000808-22)
  • 29 Sep 2017 Ferring Pharmaceuticals completes a phase III trial in Nocturia in Japan (Sublingual) (NCT02904759)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top